<DOC>
	<DOCNO>NCT00992017</DOCNO>
	<brief_summary>Both pregnant woman people infected HIV increase risk viral infection , include influenza infection . Pregnant woman infect HIV may particular risk infection new H1N1 influenza virus . This study test safety immunogenicity H1N1 influenza vaccine pregnant woman infect HIV .</brief_summary>
	<brief_title>Safety Immune Response H1N1 Influenza Vaccine HIV Infected Pregnant Women</brief_title>
	<detailed_description>On June 11 , 2009 , World Health Organization declare pandemic new H1N1 influenza virus , virus cause significant fever respiratory illness Mexico United States . Pregnant woman increase risk complication influenza . HIV infected people tend low normal antibody responses seasonal influenza vaccine . Data suggest large average dos vaccine counteract weak antibody response . Preliminary result ongoing study influenza A ( H1N1 ) 2009 monovalent vaccine indicate vaccine may increase immune activation . This study test safety antibody response high dos influenza A ( H1N1 ) 2009 monovalent vaccine pregnant woman infect HIV . Participation study last 6 month participant deliver baby 52 week . Participants receive two dos H1N1 vaccine study entry 21 day . Each dose consist two intramuscular injection ( four total injection ) . On day injection , participant baby ' heart rate check vaccination . At visit , follow-up visit Days 21 , 31 , 42 , participant complete review symptom , physical neurological exam , blood draw . For 10 day receive dose vaccine , participant ask keep track temperature symptoms reaction journal . Participants contact Day 2 Day 10 first dose vaccine give Day 2 second dose vaccine give . Some participant also receive phone call 6 month . At delivery participant 's baby , blood drawn mother umbilical cord ( baby cord blood could obtain ) . At 3 6 month delivery , participant come follow-up visit involve , mother child , review symptom , brief physical exam , blood draw ( 6 month woman clinic visit , rest receive phone call ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Step I : Confirmed diagnosis HIV1 infection Pregnant Between 14 35 week gestation Documented platelet count great 50,000 mm3 absolute neutrophil count ( ANC ) great 500 mm3 within 28 day prior study entry Able understand comply plan study procedure On antiretroviral therapy ( ART ) outline treatment guideline pregnant HIV1 infect woman . Women must currently take ART initiate ART either prior concomitantly first dose vaccine . Inclusion Criteria Step II : Received first dose influenza A ( H1N1 ) 2009 monovalent vaccine Has document platelet count great 50,000 mm3 ANC great 500 mm3 within 28 day prior Step II entry Exclusion Criteria Step I : Has know allergy egg , egg product , neomycin , polymyxin Has history , opinion site investigator , severe reaction follow previous immunization seasonal TIV Participation novel H1N1 influenza vaccine study past 2 year Proven history , reverse transcription polymerase chain reaction ( RTPCR ) , novel influenza H1N1 infection positive influenza diagnostic test since June 2009 ( specificity H1N1 require ) prior study entry Received live licensed vaccine within 4 week inactivate licensed vaccine within 2 week prior study entry Received nonlicensed agent ( vaccine , drug , biologic , device , blood product , medication ) within 4 week prior vaccination study expect receive another nonlicensed agent delivery Acute illness and/or oral temperature great equal 100.0 degree F within 24 hour prior study entry Use anticancer chemotherapy radiation therapy within precede 36 month study enrollment immunosuppression result underlie illness treatment ( HIV1 infection ) Active neoplastic disease ( exclude nonmelanoma skin cancer , human papillomavirus [ HPV ] relate cervical dysplasia , cervical intraepithelial neoplasia [ CIN ] Grades 1 , 2 , 3 ) Longterm use glucocorticoid , include oral parenteral prednisone equivalent ( least 2.0 mg/kg per day least 20 mg total dose ) 2 consecutive week ( 2 week total ) past 3 month highdose inhaled steroid ( 800 mcg/day beclomethasone dipropionate equivalent ) within past 3 month . Nasal topical steroid allow . Received immunoglobulin blood product ( exception Rho D immune globulin ) within 3 month prior enrollment study Current diagnosis uncontrolled major psychiatric disorder History GuillainBarre syndrome subject subject 's family ( include parent , sibling , halfsiblings , child ) Onset neurological disorder include ( limited ) absent ankle patellar deep tendon reflex ( DTRs ) leg ( four absent ) within past 6 month Disproportionate loss strength low extremity extremity compare upper extremity ( think relate pregnancy ) within past 6 month Any condition would , opinion site investigator , place subject unacceptable risk injury render subject unable meet requirement protocol . Pregnancy complication preterm labor , hypertension preeclampsia exclusion criterion study . Exclusion Criteria Step II : Received nonlicensed agent ( vaccine , drug , biologic , device , blood product , medication ) , participation study , since study vaccine dose # 1 expect receive another nonlicensed agent delivery Use anticancer chemotherapy radiation therapy since study vaccine dose # 1 , new diagnosis active malignancy , immunosuppressed result underlie illness ( HIV1 infection ) treatment Use glucocorticoid , include oral parenteral prednisone equivalent ( least 2.0 mg/kg per day least 20 mg total dose ) highdose inhaled steroid ( 800 mcg/day beclomethasone dipropionate equivalent ) 2 consecutive week ( 2 week total ) since study vaccine dose # 1 . Nasal topical steroid allow . Received immunoglobulin blood product ( exception Rho D immune globulin ) since study vaccine dose # 1 A new diagnosis uncontrolled major psychiatric disorder since study vaccine dose # 1 New occurrence new awareness GuillainBarre syndrome subject subject 's family ( include parent , sibling , halfsiblings , child ) since study vaccine dose # 1 A new onset neurological disorder include ( limited ) absent ankle patellar DTRs leg ( four absent ) since study vaccine dose # 1 Disproportionate loss strength low extremity extremity compare upper extremity ( think relate pregnancy ) since study vaccine dose # 1 Any Grade 3 toxicity AE experience participant unless investigator receive protocol team approval Any Grade 4 toxicity AE ( injection site reaction fever ) definitely , probably , possibly relate study vaccine dose # 1 Any Grade 4 injection site reaction fever experience subject , unless investigator receive protocol team approval Any Grade 4 AEs definitely probably related study vaccine , unless investigator receive protocol team approval Any new clinical finding since study vaccine dose # 1 , , investigator 's opinion , would compromise safety participant Participant refuse vaccination . The subject still ask complete safety visit follow study . Participant withdraws consent . Participants may withdraw consent study participation time reason , without penalty .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Pregnant</keyword>
	<keyword>Perinatal</keyword>
</DOC>